| Literature DB >> 24796669 |
Masatoshi Kadoya1, Aihiro Yamamoto1, Masahide Hamaguchi1, Hiroshi Obayashi2, Katsura Mizushima3, Mitsuhiro Ohta4, Takahiro Seno5, Ryo Oda6, Hiroyoshi Fujiwara6, Masataka Kohno1, Yutaka Kawahito7.
Abstract
Allograft inflammatory factor-1 (AIF-1) is expressed by macrophages, fibroblasts, endothelial cells and smooth muscle cells in immune-inflammatory disorders such as systemic sclerosis, rheumatoid arthritis and several vasculopathies. However, its molecular function is not fully understood. In this study, we examined gene expression profiles and induction of chemokines in monocytes treated with recombinant human AIF (rhAIF-1). Using the high-density oligonucleotide microarray technique, we compared mRNA expression profiles of rhAIF-1-stimulated CD14(+) peripheral blood mononuclear cells (CD14(+) PBMCs) derived from healthy volunteers. We demonstrated upregulation of genes for several CC chemokines such as CCL1, CCL2, CCL3, CCL7, and CCL20. Next, using ELISAs, we confirmed that rhAIF-1 promoted the secretion of CCL3/MIP-1α and IL-6 by CD14(+) PBMCs, whereas only small amounts of CCL1, CCL2/MCP-1, CCL7/MCP-3 and CCL20/MIP-3α were secreted. Conditioned media from rhAIF-1stimulated CD14(+) PBMCs resulted in migration of PBMCs. These findings suggest that AIF-1, which induced chemokines and enhanced chemotaxis of monocytes, may represent a molecular target for the therapy of immune-inflammatory disorders.Entities:
Keywords: AIF-1; Allograft inflammatory factor-1; Chemotaxis; IL-6; MIP-1α
Mesh:
Substances:
Year: 2014 PMID: 24796669 DOI: 10.1016/j.bbrc.2014.04.106
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575